Ginsenoside Rh2

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

人参皂苷 Rh2 是红参提取物，是一种有效的抗炎和抗癌化合物。

Ginsenoside Rh2 is an aldose reductase inhibitor found in Panax. It also decreases ROS levels in keratinocytes, lowers levels of amyloid-β in Alzheimer's disease models, induces β-cell proliferation, inhibits osteoclastogenesis by suppressing RANKL-induced osteoclast differentiation.(In Vitro):Ginsenoside Rh2 induces the activation of two initiator caspases, caspase-8 and caspase-9 in human cancer cells. Ginsenoside Rh2 induces cancer cell apoptosis in a multi-path manner and is therefore a promising candidate for anti-tumor drug development. Ginsenoside Rh2 triggers p53-dependent Fas expression and consequent activation of caspase-8 and p53-independent caspase-9-mediated intrinsic pathway to cause cancer cell death.The cytotoxic activity of Ginsenoside Rh2 in the human tumor cell lines HeLa, SK-HEP-1, SW480, and PC-3 is assessed by MTT. The cell viability of HeLa cells is remarkably inhibited by Ginsenoside Rh2, with an IC50 value of 2.52 μg/mL, whereas SK-HEP-1 and SW480 cells are less sensitive to Ginsenoside Rh2, with IC50 values of 3.15 μg/mL and 4.06 μg/mL, respectively. PC-3 cells are the least vulnerable to Ginsenoside Rh2, with an IC50 value of 7.85 μg/mL, 3-fold higher than HeLa cells.(In Vivo):A total of 15 days following B16-F10 cell injection, tumor sizes from the 3 tumor bearing groups are measured. The tumor sizes in the G-L group and G-H group (G-L and G-H refer to a low or high dose of ginsenoside Rh2 injection) are reduced compared with the tumor group (P<0.05). The survival analysis reveals that the Ginsenoside Rh2 treated groups survive longer than the untreated tumor group and the effect is dose-dependent (P<0.05).

——

——

Ginsenoside Rh2 | HY-N0605 | HY N0605

Others

Other Targets

EGFR

Others-Field

——

78214-33-2

622.87

C36H62O8

>98% (HPLC)

DMSO : ≥ 300 mg/mL; 481.64 mM

O[C@H]1[C@@H](O[C@@H]([C@H]([C@@H]1O)O)CO)O[C@@H]1C([C@H]2[C@@]([C@@H]3[C@]([C@]4([C@H]([C@@H](C3)O)[C@@H]([C@@](O)(CCC=C(C)C)C)CC4)C)(CC2)C)(CC1)C)(C)C

(2R,3R,4S,5S,6R)-2-(((3R,8R,9R,10R,12S,13R,14R,17S)-12-hydroxy-17-((S)-2-hydroxy-6-methylhept-5-en-2-yl)-4,4,8,10,14-pentamethylhexadecahydro-1H-cyclopenta[a]phenanthren-3-yl)oxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol

(-20℃)

With Ice Pack

≥ 2 years